Log in

NASDAQ:MYL - Mylan Stock Price, Forecast & News

$19.29
+0.39 (+2.06 %)
(As of 12/8/2019 10:38 AM ET)
Today's Range
$19.01
Now: $19.29
$19.35
50-Day Range
$17.08
MA: $18.31
$19.93
52-Week Range
$16.63
Now: $19.29
$32.23
Volume5.02 million shs
Average Volume6.01 million shs
Market Capitalization$9.96 billion
P/E Ratio4.21
Dividend YieldN/A
Beta1.71
Mylan N.V., together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic, branded-generic, brand-name, and over-the-counter (OTC) pharmaceutical products in North America, Europe, and internationally. It offers active pharmaceutical ingredients and finished dosage forms; and antiretroviral medicines to treat HIV/AIDS. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryPharmaceuticals
SectorMedical
Current SymbolNASDAQ:MYL
CUSIP62853010
Phone724-514-1800

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$11.43 billion
Cash Flow$8.85 per share
Book Value$23.60 per share

Profitability

Net Income$352.50 million

Miscellaneous

Employees35,000
Market Cap$9.96 billion
Next Earnings Date2/25/2020 (Estimated)
OptionableOptionable

Receive MYL News and Ratings via Email

Sign-up to receive the latest news and ratings for MYL and its competitors with MarketBeat's FREE daily newsletter.


Mylan (NASDAQ:MYL) Frequently Asked Questions

What is Mylan's stock symbol?

Mylan trades on the NASDAQ under the ticker symbol "MYL."

How were Mylan's earnings last quarter?

Mylan NV (NASDAQ:MYL) posted its earnings results on Tuesday, November, 5th. The company reported $1.17 earnings per share for the quarter, topping the Zacks' consensus estimate of $1.14 by $0.03. The company earned $2.96 billion during the quarter, compared to the consensus estimate of $3.01 billion. Mylan had a return on equity of 18.80% and a net margin of 0.42%. The company's revenue was up 3.5% on a year-over-year basis. During the same quarter last year, the firm earned $1.25 earnings per share. View Mylan's Earnings History.

When is Mylan's next earnings date?

Mylan is scheduled to release their next quarterly earnings announcement on Tuesday, February 25th 2020. View Earnings Estimates for Mylan.

What guidance has Mylan issued on next quarter's earnings?

Mylan updated its FY19 earnings guidance on Tuesday, November, 5th. The company provided earnings per share guidance of $4.20-4.40 for the period, compared to the Thomson Reuters consensus EPS estimate of $4.27. The company issued revenue guidance of $11.5-12.0 billion, compared to the consensus revenue estimate of $11.61 billion.

What price target have analysts set for MYL?

17 analysts have issued 1-year price targets for Mylan's shares. Their forecasts range from $18.00 to $36.00. On average, they anticipate Mylan's stock price to reach $27.59 in the next twelve months. This suggests a possible upside of 43.0% from the stock's current price. View Analyst Price Targets for Mylan.

What is the consensus analysts' recommendation for Mylan?

17 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Mylan in the last year. There are currently 6 hold ratings and 11 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Mylan.

What are Wall Street analysts saying about Mylan stock?

Here are some recent quotes from research analysts about Mylan stock:
  • 1. According to Zacks Investment Research, "Mylan received a significant boost, when the FDA approved its generic version of Advair Diskus — WixelaInhub — following a few setbacks. The biosimilars portfolio is also gaining traction with a few important approvals. However, Mylan’s generic business is experiencing a slowdown. The company proactively discontinued a number of products along with transferring some to other sites. These have led to a temporary disruption in the supply of certain products and reduced volumes in North America generic sales. The FDA approved rival Teva Pharmaceutical’s generic version of EpiPen and EpiPen Jr, which, in turn, will negatively impact sales further. Moreover, slower-than-expected uptake of generic Copaxone, even after reducing the price by more than 60%, adversely impacted sales in North America. Shares have underperformed the industry in the past six months." (4/30/2019)
  • 2. Cantor Fitzgerald analysts commented, ". We are lowering our 1Q19 EPS estimate for MYL to $0.70 from $0.88. The decrease in our estimate is based on comments the company made at a conference on 3/5/19. This does not affect our investment thesis, and we are thus maintaining our Neutral rating and 12-month PT of $41." (4/1/2019)

Has Mylan been receiving favorable news coverage?

News articles about MYL stock have trended extremely negative this week, according to InfoTrie Sentiment. The research group rates the sentiment of news coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Mylan earned a media sentiment score of -5.0 on InfoTrie's scale. They also gave media coverage about the company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an effect on the company's share price in the immediate future. View News Stories for Mylan.

Who are some of Mylan's key competitors?

What other stocks do shareholders of Mylan own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Mylan investors own include Gilead Sciences (GILD), Teva Pharmaceutical Industries (TEVA), Alibaba Group (BABA), Allergan (AGN), Starbucks (SBUX), Micron Technology (MU), Netflix (NFLX), NVIDIA (NVDA), Intel (INTC) and Celgene (CELG).

Who are Mylan's key executives?

Mylan's management team includes the folowing people:
  • Ms. Heather Bresch, CEO & Exec. Director (Age 50)
  • Mr. Rajiv Malik, Pres & Exec. Director (Age 58)
  • Mr. Kenneth S. Parks, Chief Financial Officer (Age 56)
  • Mr. Anthony Mauro, Chief Commercial Officer (Age 46)
  • Mr. Daniel M. Gallagher Jr., Advisor (Age 46)

Who are Mylan's major shareholders?

Mylan's stock is owned by a number of of institutional and retail investors. Top institutional shareholders include State Street Corp (4.45%), Menora Mivtachim Holdings LTD. (1.30%), Phoenix Holdings Ltd. (0.58%), Russell Investments Group Ltd. (0.55%), Banco Santander S.A. (0.54%) and First Trust Advisors LP (0.49%). Company insiders that own Mylan stock include Anthony Mauro, Goulds Bruce, Heather M Bresch, Melina E Higgins, Paul Campbell, Rajiv Malik, Richard A Mark, Robert J Coury and Sjoerd S Vollebregt. View Institutional Ownership Trends for Mylan.

Which institutional investors are selling Mylan stock?

MYL stock was sold by a variety of institutional investors in the last quarter, including State of New Jersey Common Pension Fund D, Point72 Asset Management L.P., Russell Investments Group Ltd., SG Americas Securities LLC, Stifel Financial Corp, Squarepoint Ops LLC, Andra AP fonden and State of Tennessee Treasury Department. View Insider Buying and Selling for Mylan.

Which institutional investors are buying Mylan stock?

MYL stock was acquired by a variety of institutional investors in the last quarter, including Phoenix Holdings Ltd., Banco Santander S.A., Parametric Portfolio Associates LLC, First Trust Advisors LP, State Street Corp, Menora Mivtachim Holdings LTD., California Public Employees Retirement System and Gabelli Funds LLC. Company insiders that have bought Mylan stock in the last two years include Melina E Higgins, Richard A Mark, Robert J Coury and Sjoerd S Vollebregt. View Insider Buying and Selling for Mylan.

How do I buy shares of Mylan?

Shares of MYL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Mylan's stock price today?

One share of MYL stock can currently be purchased for approximately $19.29.

How big of a company is Mylan?

Mylan has a market capitalization of $9.96 billion and generates $11.43 billion in revenue each year. The company earns $352.50 million in net income (profit) each year or $4.58 on an earnings per share basis. Mylan employs 35,000 workers across the globe.View Additional Information About Mylan.

What is Mylan's official website?

The official website for Mylan is http://www.mylan.com/.

How can I contact Mylan?

Mylan's mailing address is 1000 MYLAN BOULEVARD, CANONSBURG PA, 15317. The company can be reached via phone at 724-514-1800 or via email at [email protected]


MarketBeat Community Rating for Mylan (NASDAQ MYL)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  722 (Vote Outperform)
Underperform Votes:  581 (Vote Underperform)
Total Votes:  1,303
MarketBeat's community ratings are surveys of what our community members think about Mylan and other stocks. Vote "Outperform" if you believe MYL will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MYL will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/8/2019 by MarketBeat.com Staff

Featured Article: What is a Lock-Up Period?

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel